Bachem Holding AG Business Summary

Bachem Holding AG operates as a leading global Contract Development and Manufacturing Organization (CDMO) specializing in the large-scale production of peptides and oligonucleotides. The company generates revenue through three primary channels: the manufacturing of commercial Active Pharmaceutical Ingredients (APIs), custom synthesis services for clinical-stage drug candidates, and the sale of a specialized catalog of over 3,000 research chemicals. Its business segments are strategically aligned with the "TIDES" (peptides and oligonucleotides) market, with a significant portion of current growth driven by long-term supply contracts for metabolic disorder treatments, specifically GLP-1 receptor agonists. Bachem maintains a dominant market position as the world's largest independent peptide manufacturer, competing directly with PolyPeptide Group, Lonza, and WuXi AppTec. Unlike broader CDMOs, Bachem’s competitive advantage lies in its specialized chemical process engineering and its massive capacity expansions, such as the Sisslerfeld facility, which allow it to achieve economies of scale that smaller niche players cannot match. Founded in 1971 by Peter Grogg, who remains a dominant shareholder via Ingro Finanz AG, the company is managed by an executive team with deep technical and pharmaceutical pedigree. Dr. Thomas Meier serves as the Chief Executive Officer, having led the company through significant capacity scaling since 2019 following a long tenure on the Executive Committee. The technical leadership is anchored by Dr. Guenther Loidl, the Chief Technology Officer, who oversees the complex chemical innovations required for large-scale oligonucleotide and peptide synthesis. Financial operations are directed by CFO Alain Steiner, who joined the group to manage the capital-intensive expansion phase. The Board of Directors is chaired by Dr. Kuno Sommer, a veteran of the life sciences industry with extensive experience at Roche. This leadership team is supported by a stable investor base, including significant holdings by the founder and Swiss institutional investors, positioning the firm as a critical infrastructure provider for the global biotechnology sector.